Institution
Korea University
Education•Seoul, South Korea•
About: Korea University is a education organization based out in Seoul, South Korea. It is known for research contribution in the topics: Population & Thin film. The organization has 39756 authors who have published 82424 publications receiving 1860927 citations. The organization is also known as: Bosung College & Bosung Professional College.
Topics: Population, Thin film, Catalysis, Large Hadron Collider, Cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Recent findings on the roles of MAPK signaling pathways in human disorders, focusing on cancer and neurodegenerative diseases including AD, PD, and ALS are summarized.
1,929 citations
••
TL;DR: In this critical review, the fluorescent and colorimetric sensors are classified according to their receptors into several categories, including small molecule based sensors, calixarene based Chemosensors, BODIPY based chemosensor, polymer based chemOSensors), DNA functionalized sensing systems, protein based sensing systems and nanoparticle based sensing Systems.
Abstract: Exposure to even very low levels of lead, cadmium, and mercury ions is known to cause neurological, reproductive, cardiovascular, and developmental disorders, which are more serious problems for children particularly. Accordingly, great efforts have been devoted to the development of fluorescent and colorimetric sensors, which can selectively detect lead, cadmium, and mercury ions. In this critical review, the fluorescent and colorimetric sensors are classified according to their receptors into several categories, including small molecule based sensors, calixarene based chemosensors, BODIPY based chemosensors, polymer based chemosensors, DNA functionalized sensing systems, protein based sensing systems and nanoparticle based sensing systems (197 references).
1,920 citations
••
Seoul National University1, Hebrew University of Jerusalem2, University of Seville3, University of Copenhagen4, University of Valencia5, University of Coimbra6, United States Department of Agriculture7, Korea University8, State Oceanic Administration9, Murdoch University10, University of Salamanca11
TL;DR: The minimal standards for the quality of genome sequences and how they can be applied for taxonomic purposes are described.
Abstract: Advancement of DNA sequencing technology allows the routine use of genome sequences in the various fields of microbiology. The information held in genome sequences proved to provide objective and reliable means in the taxonomy of prokaryotes. Here, we describe the minimal standards for the quality of genome sequences and how they can be applied for taxonomic purposes.
1,908 citations
••
TL;DR: The Quantum Toolbox in Python as mentioned in this paper has been updated with new features, enhanced performance, and made changes in the API for improved functionality and consistency within the package, as well as increased compatibility with existing conventions used in other scientific software packages for Python.
1,780 citations
••
TL;DR: The combination of ramucirumab with pac litaxel significantly increases overall survival compared with placebo plus paclitaxel, and could be regarded as a new standard second-line treatment for patients with advanced gastric cancer.
Abstract: Summary Background VEGFR-2 has a role in gastric cancer pathogenesis and progression. We assessed whether ramucirumab, a monoclonal antibody VEGFR-2 antagonist, in combination with paclitaxel would increase overall survival in patients previously treated for advanced gastric cancer compared with placebo plus paclitaxel. Methods This randomised, placebo-controlled, double-blind, phase 3 trial was done at 170 centres in 27 countries in North and South America, Europe, Asia, and Australia. Patients aged 18 years or older with advanced gastric or gastro-oesophageal junction adenocarcinoma and disease progression on or within 4 months after first-line chemotherapy (platinum plus fluoropyrimidine with or without an anthracycline) were randomly assigned with a centralised interactive voice or web-response system in a 1:1 ratio to receive ramucirumab 8 mg/kg or placebo intravenously on days 1 and 15, plus paclitaxel 80 mg/m 2 intravenously on days 1, 8, and 15 of a 28-day cycle. A permuted block randomisation, stratified by geographic region, time to progression on first-line therapy, and disease measurability, was used. The primary endpoint was overall survival. Efficacy analysis was by intention to treat, and safety analysis included all patients who received at least one treatment with study drug. This trial is registered with ClinicalTrials.gov, number NCT01170663, and has been completed; patients who are still receiving treatment are in the extension phase. Findings Between Dec 23, 2010, and Sept 23, 2012, 665 patients were randomly assigned to treatment—330 to ramucirumab plus paclitaxel and 335 to placebo plus paclitaxel. Overall survival was significantly longer in the ramucirumab plus paclitaxel group than in the placebo plus paclitaxel group (median 9·6 months [95% CI 8·5–10·8] vs 7·4 months [95% CI 6·3–8·4], hazard ratio 0·807 [95% CI 0·678–0·962]; p=0·017). Grade 3 or higher adverse events that occurred in more than 5% of patients in the ramucirumab plus paclitaxel group versus placebo plus paclitaxel included neutropenia (133 [41%] of 327 vs 62 [19%] of 329), leucopenia (57 [17%] vs 22 [7%]), hypertension (46 [14%] vs eight [2%]), fatigue (39 [12%] vs 18 [5%]), anaemia (30 [9%] vs 34 [10%]), and abdominal pain (20 [6%] vs 11 [3%]). The incidence of grade 3 or higher febrile neutropenia was low in both groups (ten [3%] vs eight [2%]). Interpretation The combination of ramucirumab with paclitaxel significantly increases overall survival compared with placebo plus paclitaxel, and could be regarded as a new standard second-line treatment for patients with advanced gastric cancer. Funding Eli Lilly and Company.
1,778 citations
Authors
Showing all 40083 results
Name | H-index | Papers | Citations |
---|---|---|---|
Anil K. Jain | 183 | 1016 | 192151 |
Hyun-Chul Kim | 176 | 4076 | 183227 |
Yongsun Kim | 156 | 2588 | 145619 |
Jongmin Lee | 150 | 2257 | 134772 |
Byung-Sik Hong | 146 | 1557 | 105696 |
Daniel S. Berman | 141 | 1363 | 86136 |
Christof Koch | 141 | 712 | 105221 |
David Y. Graham | 138 | 1047 | 80886 |
Suyong Choi | 135 | 1495 | 97053 |
Rudolph E. Tanzi | 135 | 638 | 85376 |
Sung Keun Park | 133 | 1567 | 96933 |
Tae Jeong Kim | 132 | 1420 | 93959 |
Robert S. Brown | 130 | 1243 | 65822 |
Mohammad Khaja Nazeeruddin | 129 | 646 | 85630 |
Klaus-Robert Müller | 129 | 764 | 79391 |